Clover Biopharmaceuticals names Nicholas Jackson as president of global R&D

Clover Biopharmaceuticals Ltd. (HKEX: 02197) appointed Nicholas Jackson as President of Global R&D and Alliances, according to a company statement. Jackson will work with CEO Joshua Liang to advance development of the company's RSV+hMPV±PIV3 combination vaccine candidates and lead potential partnerships with global collaborators.

Jackson returns to Clover after previously holding leadership positions at GSK, Pfizer and Sanofi, where he served as Head of Global Research for Sanofi Pasteur. Most recently, he was Executive Director and CEO of the Novo Nordisk Foundation Initiative for Vaccines and Immunity.

"His extensive experience in leading global cross-border vaccine development and partnerships will be invaluable as we continue to advance our potential best-in-class and first-in-class RSV+hMPV±PIV3 combination vaccine candidates leveraging our validated Trimer-Tag platform," said Liang.

Jackson said he looks forward to advancing opportunities for Clover's combination vaccine candidates, which recently announced positive Phase I clinical data in older adults. He noted that Clover's Trimer-Tag platform technology has a clinical safety database of over 40,000 doses and demonstrated commercial manufacturing scalability.

Jackson has spent over 27 years in vaccine and infectious disease research and development, leading programs targeting viral and bacterial infectious diseases. He holds degrees from Oxford Brookes University, London School of Hygiene & Tropical Medicine, and a doctorate from the University of Warwick in viral immunology.

Clover Biopharmaceuticals is a commercial-stage biotechnology company focused on vaccine development and manufacturing.

You May Also Be Interested In

• Heidi L. O'Neill resigns from Lithia Motors board
• Kontoor Brands adds two directors, expands board to nine
• Teladoc Health names new chief legal officer after 11-year tenure